Samantha Daniels

Samantha Daniels is Of Counsel in Pomerantz’s New York office, where she prosecutes securities fraud on behalf of institutional and individual investors.  She joined the Firm in 2024 and has since served as lead counsel in cases spanning the pharmaceutical, biotechnology, technology, and entertainment industries.

Samantha brings to her plaintiff-side practice a rare depth of experience defending the same kinds of claims she now prosecutes. Before joining Pomerantz, she was an associate at Gibson, Dunn & Crutcher LLP, principally in the firm’s nationally recognized appellate and constitutional law practice, where she represented high-profile clients in securities litigation, consumer protection, labor and employment, and constitutional matters. Among other engagements, she helped resolve questions of first impression concerning the employment status of gig-economy workers on behalf of Uber and Postmates, secured the dismissal of consumer fraud claims against Apple concerning FaceTime, and was part of the team that recovered $2.1 billion for NML Capital on defaulted Argentine sovereign bonds.

Some of Samantha’s representative legal matters include:

In re SunPower Corporation Securities Litigation, No. 3:23‑cv‑05544‑RFL (N.D. Cal.). Securities fraud class action alleging that former SunPower executives concealed the deterioration of the Company’s financial condition during a liquidity crisis that ended in the resignation of its auditor, government investigations, and bankruptcy. As lead counsel, Ms. Daniels investigated the claims through several amended complaints, drafted the oppositions to defendants’ successive motions to dismiss and argued them before the Court, defeating dismissal of plaintiffs’ core claims, including an August 2023 “going concern” misrepresentation. She then led the mediation and settlement negotiations that produced an $11 million all‑cash settlement, approximately 23% of the most likely recoverable damages.

Shih v. Amylyx Pharmaceuticals, Inc., No. 24‑cv‑12068‑NMG (D. Mass.). Securities fraud class action alleging that Amylyx and its senior executives touted robust demand for the Company’s ALS drug, Relyvrio, while concealing a patient‑discontinuation rate that ultimately exceeded 50%; the stock fell nearly 32% when the truth emerged. As lead counsel, Ms. Daniels investigated the claims and drafted the opposition to defendants’ motion to dismiss, which the Court denied on the papers, sustaining the core Section 10(b) claims. Ms. Daniels negotiated the settlement of $6.5 million.

In re Gritstone bio, Inc. Securities Litigation, No. 24‑cv‑03640‑CRB (N.D. Cal.). Securities fraud class action alleging that Gritstone’s CEO overstated the Company’s cGMP compliance and its ability to manufacture a vaccine under a $423 million BARDA contract; the Company later filed for bankruptcy. As lead counsel, Ms. Daniels pursued the claims from former employees in two rounds of amended complaints, drafted the oppositions to two motions to dismiss, and secured a ruling that the manufacturing‑compliance misrepresentations were adequately alleged.   She led the mediation that produced a $6 million all‑cash settlement.

Patange v. Golden Heaven Group Holdings Ltd., No. 2:23-cv-10619-HDV-SK (C.D. Cal.). Securities class action arising from the 2023 U.S. IPO of a purported operator of six Chinese amusement parks whose offering documents misrepresented the parks’ condition, attendance, and revenue.  In reality, the parks were largely deserted and had been acquired for $7.5 million a year before the IPO valued them at $200 million. Plaintiff sued the issuer and its IPO gatekeepers—the underwriters, U.S. representative, and auditor—under Sections 11 and 10(b). As lead counsel, Ms. Daniels investigated the claims, drafted the oppositions to defendants’ motions to dismiss and argued them; the Court denied the motions in their entirety, sustaining every claim against every defendant. To Ms. Daniels’ knowledge, it is the first decision to sustain securities claims against a U.S. representative based on its role as registered agent. The case settled for $1.9 million.

Vreeland v. Metagenomi Inc., No. 5:24‑cv‑06765‑EKL (N.D. Cal.). Securities Act class action arising from the February 2024 IPO of a genetic‑medicines company whose registration statement touted the progress of its research collaboration with Moderna when, as former employees confirmed, the partnership had already broken down; it was terminated less than three months after the IPO. As lead counsel, Ms. Daniels investigated and added the later-sustained claims about the certain Moderna programs, drafted the opposition to defendants’ motion to dismiss, and in March 2026 the Court sustained the core Section 11 claims and the related Section 15 control‑person claim on the papers.

Samantha earned her J.D. from the University of Chicago Law School, where she published a student comment on consumer protection law.  She received her B.A. from Cornell University with degrees in Political Science and History.

Show More